Compare TRST & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRST | PHAR |
|---|---|---|
| Founded | 1902 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 858.9M | 1.2B |
| IPO Year | 1994 | 2020 |
| Metric | TRST | PHAR |
|---|---|---|
| Price | $51.04 | $13.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | ★ 70.9K | 12.2K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | ★ 26.46 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ $55.68 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.17 | $9.54 |
| 52 Week High | $52.19 | $21.34 |
| Indicator | TRST | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 65.72 | 45.18 |
| Support Level | $41.96 | $12.98 |
| Resistance Level | N/A | $17.80 |
| Average True Range (ATR) | 0.95 | 0.45 |
| MACD | 0.10 | 0.13 |
| Stochastic Oscillator | 69.09 | 96.89 |
Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company derives revenue from the business of Banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.